Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821860 | 0.86 | FAAH (0.70) | FAAHKDM4ESMN1; SMN2ALDH1A1KMT2A | |
| Water SCHEMBL6743398 | 0.84 | FAAH (0.68) | FAAHKDM4ESMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL10254050 | 0.84 | MEN1 (0.60) | FAAHKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL3606265 | 0.81 | FAAH (1.00) | FAAHKDM4EMAPT | |
| SCHEMBL25040649 | 0.78 | ALDH1A1 (0.57) | FAAHKDM4ESMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL1821910 | 0.76 | KDR (0.55) | FAAHKDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL22361385 | 0.76 | KDM4E (0.63) | FAAHKDM4ESMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18292063 | 0.76 | KDM4E (0.63) | FAAHKDM4ESMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18292042 | 0.76 | KDM4E (0.63) | FAAHKDM4ESMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL10076259 | 0.75 | KDM4E (0.74) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | FAAH 4106/4885KDM4E 4094/4885SMN1; SMN2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.